Abstract.
We have previously shown that a ditriazine derivative 4,10-dichloropyrido[5,6:4,5]thieno[3,2-d′:3,2-d]-1, 2, 3-ditriazine (DTD) modulates acute inflammation in murine models by inhibition of leukocyte functions and expression of inducible enzymes including nitric oxide synthase and cyclooxygenase-2 (COX-2). In the present work, we have demonstrated the anti-inflammatory effect of DTD after oral administration in the rat adjuvant-induced arthritis, by reduction of interleukin-1β and tumour necrosis factor-α levels and COX-2 expression in the inflamed tissues. These mediators were also significantly decreased by DTD treatment in the angiogenesis-dependent murine air pouch granuloma model, where this agent exerted anti-inflammatory and antiangiogenic effects. In vitro experiments indicated that DTD is an inhibitor of the nuclear factor-κB (NF-κB) pathway of cellular activation in macrophages, in parallel with the regulation of cytokine release. Our results suggest that the anti-inflammatory and antiangiogenic properties of DTD can be related to the inhibition of cytokine and PGE2 production by interfering with NF-κB activation. This compound thus offers a therapeutic potential for the treatment of chronic inflammatory diseases with an angiogenic component, such as rheumatoid arthritis.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Rioja, I., Terencio, C.M., Ubeda, A. et al. A new ditriazine inhibitor of NF-κB modulates chronic inflammation and angiogenesis. Naunyn-Schmiedeberg's Arch Pharmacol 365, 357–364 (2002). https://doi.org/10.1007/s00210-002-0544-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00210-002-0544-z